$EKSO
EKSO BIONICS HOLDINGS, INC.

2021 Q4 Form 10-K Financial Statement

#000154908422000006 Filed on February 24, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $4.076M $11.25M $2.250M
YoY Change 81.16% 26.62% -39.52%
Cost Of Revenue $1.661M $4.497M $890.0K
YoY Change 86.63% 17.97% -52.41%
Gross Profit $2.415M $6.749M $1.360M
YoY Change 77.57% 33.12% -26.88%
Gross Profit Margin 59.25% 60.01% 60.44%
Selling, General & Admin $6.149M $17.83M $3.650M
YoY Change 68.47% 15.37% -11.19%
% of Gross Profit 254.62% 264.17% 268.38%
Research & Development $818.0K $2.748M $710.0K
YoY Change 15.21% 11.08% 26.79%
% of Gross Profit 33.87% 40.72% 52.21%
Depreciation & Amortization $130.0K $561.0K $150.0K
YoY Change -13.33% -9.52% -11.76%
% of Gross Profit 5.38% 8.31% 11.03%
Operating Expenses $6.967M $20.58M $4.360M
YoY Change 59.79% 12.07% -7.04%
Operating Profit -$4.552M -$13.83M -$3.000M
YoY Change 51.73% 4.04% 6.01%
Interest Expense -$236.0K $113.0K -$30.00K
YoY Change 686.67% -18.71% -57.14%
% of Operating Profit
Other Income/Expense, Net $1.925M $4.064M -$950.0K
YoY Change -302.63% -260.38% -600.0%
Pretax Income -$2.863M -$9.764M -$3.980M
YoY Change -28.07% -38.3% 46.32%
Income Tax
% Of Pretax Income
Net Earnings -$2.863M -$9.764M -$3.980M
YoY Change -28.07% -38.3% 46.32%
Net Earnings / Revenue -70.24% -86.82% -176.89%
Basic Earnings Per Share -$0.80
Diluted Earnings Per Share -$225.7K -$0.88 -$477.2K
COMMON SHARES
Basic Shares Outstanding 12.66M shares 12.19M shares 8.316M shares
Diluted Shares Outstanding 12.27M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.41M $40.41M $12.86M
YoY Change 214.2% 214.2% 18.31%
Cash & Equivalents $40.41M $12.86M
Short-Term Investments
Other Short-Term Assets $485.0K $485.0K $190.0K
YoY Change 155.26% 155.26% -20.83%
Inventory $2.242M $2.242M $1.978M
Prepaid Expenses
Receivables $4.662M $4.662M $3.224M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $47.80M $47.80M $18.42M
YoY Change 159.47% 159.47% -2.06%
LONG-TERM ASSETS
Property, Plant & Equipment $991.0K $1.207M $1.172M
YoY Change -15.44% -35.11% -29.27%
Goodwill $0.00 $0.00
YoY Change -100.0%
Intangibles $0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets $164.0K $164.0K $320.0K
YoY Change -48.75% -48.75% 79.78%
Total Long-Term Assets $1.371M $1.371M $2.177M
YoY Change -37.02% -37.11% -29.95%
TOTAL ASSETS
Total Short-Term Assets $47.80M $47.80M $18.42M
Total Long-Term Assets $1.371M $1.371M $2.177M
Total Assets $49.17M $49.17M $20.60M
YoY Change 138.7% 138.67% -6.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.107M $3.107M $1.501M
YoY Change 107.0% 107.13% -21.12%
Accrued Expenses $2.299M $2.439M $1.429M
YoY Change 60.88% 26.37% -15.09%
Deferred Revenue $1.220M $1.496M
YoY Change -18.45% 0.27%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $6.855M $6.855M $4.974M
YoY Change 37.82% 37.93% -36.49%
LONG-TERM LIABILITIES
Long-Term Debt $1.993M $1.993M $1.989M
YoY Change 0.2% -35.29% 388.7%
Other Long-Term Liabilities $74.00K $3.099M $38.00K
YoY Change 94.74% -61.79% -47.22%
Total Long-Term Liabilities $2.067M $5.092M $2.027M
YoY Change 1.97% -54.5% 323.17%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.855M $6.855M $4.974M
Total Long-Term Liabilities $2.067M $5.092M $2.027M
Total Liabilities $11.95M $11.95M $16.16M
YoY Change -26.08% -26.07% 6.91%
SHAREHOLDERS EQUITY
Retained Earnings -$208.9M -$199.1M
YoY Change 4.9% 8.63%
Common Stock $13.00K $8.000K
YoY Change 62.5% 33.33%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $37.22M $37.22M $4.434M
YoY Change
Total Liabilities & Shareholders Equity $49.17M $49.17M $20.60M
YoY Change 138.7% 138.67% -6.01%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.863M -$9.764M -$3.980M
YoY Change -28.07% -38.3% 46.32%
Depreciation, Depletion And Amortization $130.0K $561.0K $150.0K
YoY Change -13.33% -9.52% -11.76%
Cash From Operating Activities -$3.075M -$11.16M -$1.740M
YoY Change 76.72% 27.42% 16.78%
INVESTING ACTIVITIES
Capital Expenditures $1.000K $59.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $1.000K -$59.00K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $37.30M
YoY Change 426.62%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $38.71M 0.000
YoY Change 261.66% -100.0%
NET CHANGE
Cash From Operating Activities -3.075M -$11.16M -1.740M
Cash From Investing Activities 1.000K -$59.00K 0.000
Cash From Financing Activities 0.000 $38.71M 0.000
Net Change In Cash -3.074M $27.54M -1.740M
YoY Change 76.67% 1284.12% -162.59%
FREE CASH FLOW
Cash From Operating Activities -$3.075M -$11.16M -$1.740M
Capital Expenditures $1.000K $59.00K $0.00
Free Cash Flow -$3.076M -$11.22M -$1.740M
YoY Change 76.78% 28.1% 16.78%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001549084
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2021Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
CY2020Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.067
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-37854
CY2021 dei Entity Registrant Name
EntityRegistrantName
Ekso Bionics Holdings, Inc.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
99-0367049
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
1414 Harbour Way South
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 1201
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
Richmond
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94804
CY2021 dei City Area Code
CityAreaCode
510
CY2021 dei Local Phone Number
LocalPhoneNumber
984-1761
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2021 dei Trading Symbol
TradingSymbol
EKSO
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
63807354 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12692919 shares
CY2021 dei Auditor Name
AuditorName
WithumSmith+Brown, PC
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California
CY2021 dei Auditor Firm
AuditorFirmId
100
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40406000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12862000 USD
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
28000 USD
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
42000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4662000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3224000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
2242000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
485000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
356000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
47795000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
18420000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
991000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
216000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
685000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
164000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
320000 USD
CY2021Q4 us-gaap Assets
Assets
49166000 USD
CY2020Q4 us-gaap Assets
Assets
20597000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3107000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1501000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1220000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
548000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
6855000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4974000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1475000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2021Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
1993000 USD
CY2020Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
3075000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
233000 USD
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
1550000 USD
CY2020Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
6037000 USD
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
74000 USD
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
11947000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
16163000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
8000 USD
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12693000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12693000 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8349000 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8349000 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000 USD
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
246090000 USD
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
204376000 USD
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-17000 USD
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-847000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208867000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-199103000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37219000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
49166000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
20597000 USD
CY2020 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7752000 USD
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11246000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4497000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3812000 USD
CY2021 us-gaap Gross Profit
GrossProfit
6749000 USD
CY2020 us-gaap Gross Profit
GrossProfit
5070000 USD
CY2021 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7305000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2748000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2474000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10524000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7702000 USD
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2021 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2020 us-gaap Restructuring Charges
RestructuringCharges
244000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
20577000 USD
CY2021 us-gaap Interest Expense
InterestExpense
113000 USD
CY2020 us-gaap Interest Expense
InterestExpense
139000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
18361000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-13828000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-13291000 USD
CY2021 ekso Warrant Issuance Expense
WarrantIssuanceExpense
0 USD
CY2020 ekso Warrant Issuance Expense
WarrantIssuanceExpense
329000 USD
CY2021 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
3962000 USD
CY2020 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-3056000 USD
CY2021 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
1099000 USD
CY2020 ekso Gain Loss On Warrant Modification
GainLossOnWarrantModification
0 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-884000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
990000 USD
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4064000 USD
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2534000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9764000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
830000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-897000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8934000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16722000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12193000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7164000 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12269000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7164000 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
6797000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2020 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7082000 USD
CY2020 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
7310000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
155000 USD
CY2020 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
50000 USD
CY2020 ekso Adjustments To Additional Paid In Capital Warrant Issuance
AdjustmentsToAdditionalPaidInCapitalWarrantIssuance
2322000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2084000 USD
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-897000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
4434000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9764000 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
35360000 USD
CY2021 ekso Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
3878000 USD
CY2021 us-gaap Stock Issued During Period Value Employee Benefit Plan
StockIssuedDuringPeriodValueEmployeeBenefitPlan
152000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2329000 USD
CY2021 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
830000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
37219000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-9764000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-15825000 USD
CY2021 us-gaap Depreciation
Depreciation
561000 USD
CY2020 us-gaap Depreciation
Depreciation
620000 USD
CY2021 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
75000 USD
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
65000 USD
CY2021 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
1099000 USD
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2021 ekso Common Stock Contribution
CommonStockContribution
171000 USD
CY2020 ekso Common Stock Contribution
CommonStockContribution
169000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2329000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
2410000 USD
CY2021 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0 USD
CY2020 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
329000 USD
CY2021 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
3962000 USD
CY2020 ekso Gain Loss On Warrant Liability
GainLossOnWarrantLiability
-3056000 USD
CY2021 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-134000 USD
CY2020 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-56000 USD
CY2021 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-867000 USD
CY2020 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
947000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1624000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-1754000 USD
CY2021 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
752000 USD
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-379000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-481000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-247000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1612000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-402000 USD
CY2021 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
379000 USD
CY2020 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-876000 USD
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-564000 USD
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
21000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11156000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8755000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
59000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37295000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7082000 USD
CY2021 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0 USD
CY2020 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
1278000 USD
CY2021 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
0 USD
CY2020 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1512000 USD
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1417000 USD
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3334000 USD
CY2021 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3078000 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
38712000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10704000 USD
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47000 USD
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27544000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
1990000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10872000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40406000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12862000 USD
CY2021 us-gaap Income Taxes Paid
IncomeTaxesPaid
104000 USD
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
109000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
1000 USD
CY2020 us-gaap Interest Paid Net
InterestPaidNet
6000 USD
CY2021 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
2461000 USD
CY2020 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
3976000 USD
CY2021 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
152000 USD
CY2020 ekso Shares Issued Capital Contribution
SharesIssuedCapitalContribution
155000 USD
CY2021 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
434000 USD
CY2020 ekso Transfer Of Property And Equipment From Inventory
TransferOfPropertyAndEquipmentFromInventory
132000 USD
CY2021 us-gaap Stock Issued1
StockIssued1
0 USD
CY2020 us-gaap Stock Issued1
StockIssued1
50000 USD
CY2021 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
1936000 USD
CY2020 ekso Fair Value Of Warrants Issued Upon Equity Financing
FairValueOfWarrantsIssuedUponEquityFinancing
0 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208867000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11156000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40406000 USD
CY2021Q4 ekso Debt Covenant Covenant Compliance Unrestricted Cash
DebtCovenantCovenantComplianceUnrestrictedCash
2000000 USD
CY2021 ekso Unrestricted Cash
UnrestrictedCash
38406000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet, and the reported amounts of revenues and expenses during the reporting period. For the Company, these estimates include, but are not limited to, revenue recognition, deferred revenue, the valuation of warrants and employee stock options, future warranty costs, accounting for leases, useful lives assigned to long-lived assets, valuation of inventory, realizability of deferred tax assets, and contingencies. Actual results could differ from those estimates.</span></div>
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and accounts receivable. The Company maintains cash accounts in excess of federally insured limits. However, the Company believes it is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. The Company extends credit to customers in the normal course of business and performs ongoing credit evaluations of its customers. Concentrations of credit risk with respect to accounts receivable exist to the full extent of amounts presented in the consolidated financial statements. The Company does not require collateral from its customers to secure accounts receivable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable are derived from the sale of products shipped and services performed for customers primarily located in the U.S., Europe, Asia, and Australia. Invoices are aged based on contractual terms with the customer. The Company reviews accounts receivable for collectability and provides an allowance for potential credit losses. The Company has not experienced material losses related to accounts receivable during the years ended December 31, 2021 and 2020. Many of the sales contracts with customers outside of the U.S. are settled in a foreign currency other than the U.S. dollar. The Company does not enter into any foreign currency hedging agreements and is susceptible to gains and losses from foreign currency fluctuations. To date, the Company has not experienced significant gains or losses upon settling contracts denominated in a foreign currency.</span></div>
CY2021Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2061000 USD
CY2020Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
1724000 USD
CY2021Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
145000 USD
CY2020Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
18000 USD
CY2021Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
36000 USD
CY2020Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
236000 USD
CY2021Q4 us-gaap Inventory Net
InventoryNet
2242000 USD
CY2020Q4 us-gaap Inventory Net
InventoryNet
1978000 USD
CY2020Q2 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2020 us-gaap Restructuring Charges
RestructuringCharges
244000 USD
CY2021 us-gaap Restructuring Charges
RestructuringCharges
0 USD
CY2021 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 USD
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0 USD
CY2020Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
189000 USD
CY2020 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9764000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15825000 USD
CY2021 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1029000 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10793000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15825000 USD
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12193000 shares
CY2020 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
7164000 shares
CY2021 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
76000 shares
CY2020 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0 shares
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12269000 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
7164000 shares
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.80
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.21
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.88
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.21
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2066000 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1997000 shares
CY2020 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-66000 USD
CY2021 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0 USD
CY2021Q4 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2349000 USD
CY2020Q4 ekso Contract With Customer Liability Extended Maintenance And Support
ContractWithCustomerLiabilityExtendedMaintenanceAndSupport
2902000 USD
CY2021Q4 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
280000 USD
CY2020Q4 ekso Contract With Customer Liability Royalties
ContractWithCustomerLiabilityRoyalties
282000 USD
CY2021Q4 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
66000 USD
CY2020Q4 ekso Contract With Customer Liability Devices And Advances
ContractWithCustomerLiabilityDevicesAndAdvances
118000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2695000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2021Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1220000 USD
CY2020Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1496000 USD
CY2021Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1475000 USD
CY2020Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1806000 USD
CY2020Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
3302000 USD
CY2021 ekso Contract With Customer Liability Deferral Of Revenue
ContractWithCustomerLiabilityDeferralOfRevenue
1189000 USD
CY2021 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1796000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2695000 USD
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
2695000 USD
CY2021Q4 us-gaap Lessor Operating Lease Term Of Contract
LessorOperatingLeaseTermOfContract
P12M
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11246000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4662000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3224000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1220000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
698000 USD
CY2021Q4 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
777000 USD
CY2021Q4 ekso Contractwith Customer Liability Non Cancellable Backlog
ContractwithCustomerLiabilityNonCancellableBacklog
1218000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5730000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5829000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4739000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
4657000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
991000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1172000 USD
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
561000 USD
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
620000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2015000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1194000 USD
CY2021Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
195000 USD
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
188000 USD
CY2021Q4 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
89000 USD
CY2020Q4 ekso Accrued Clinical Cost Current
AccruedClinicalCostCurrent
47000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2299000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1429000 USD
CY2021 us-gaap Standard Product Warranty Description
StandardProductWarrantyDescription
Sales of devices generally include an initial warranty for parts and services for one year in the Americas, two years in Europe, the Middle East, Africa (EMEA), and one or two years in the Asia Pacific (APAC) region.
CY2020 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.0849
CY2020Q3 us-gaap Payments Of Debt Extinguishment Costs
PaymentsOfDebtExtinguishmentCosts
1512000 USD
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40406000 USD
CY2021 us-gaap Interest Expense
InterestExpense
113000 USD
CY2020 us-gaap Interest Expense
InterestExpense
139000 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
0 USD
CY2021Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
2000000 USD
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
2000000 USD
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
7000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1993000 USD
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0 USD
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1993000 USD
CY2021Q4 us-gaap Long Term Debt
LongTermDebt
1993000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
233000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
233000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
229000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
229000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
229000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y5M8D
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.105
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
527000 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
537000 USD
CY2021 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
171000 USD
CY2020 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
169000 USD
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
141429000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12693000 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12693000 shares
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020 ekso Proceeds From Issuance Of Common Stock Preference Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
1436000 USD
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
8.06
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1325000 shares
CY2021 ekso Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
273000 shares
CY2021 ekso Class Of Warrant Or Right Expired
ClassOfWarrantOrRightExpired
0 shares
CY2021 ekso Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
358000 shares
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
1240000 shares
CY2021 ekso Proceeds From Issuance Of Common Stock Preference Stock And Warrants
ProceedsFromIssuanceOfCommonStockPreferenceStockAndWarrants
1417000 USD
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
137000 shares
CY2015 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
111000 shares
CY2017Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
67000 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
293000 shares
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
233000 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
333000 shares
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
800000 shares
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
491000 shares
CY2021 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P6Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Exercise Price Beginning Balance1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
32.53
CY2021Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
405000 shares
CY2021Q4 us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
36.41
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0144
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.017
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y3M7D
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.02
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2329000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2410000 USD
CY2020Q4 ekso Deferred Tax Assets Operating Lease Right Of Use Asset
DeferredTaxAssetsOperatingLeaseRightOfUseAsset
110000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-9069000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-15825000 USD
CY2021 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14954000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-695000 USD
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-871000 USD
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9764000 USD
CY2021 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Deferred Federal State And Local Tax Expense Benefit
DeferredFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2020 us-gaap Current Federal State And Local Tax Expense Benefit
CurrentFederalStateAndLocalTaxExpenseBenefit
0 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.313
CY2020 ekso Effective Income Tax Rate Reconciliation Loan Forgiveness
EffectiveIncomeTaxRateReconciliationLoanForgiveness
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.019
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
-0.004
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.166
CY2021 ekso Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant
EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
0.085
CY2020 ekso Effective Income Tax Rate Reconciliation Unrealized Gain Loss On Warrant
EffectiveIncomeTaxRateReconciliationUnrealizedGainLossOnWarrant
-0.045
CY2021 ekso Effective Income Tax Rate Reconciliation Loan Forgiveness
EffectiveIncomeTaxRateReconciliationLoanForgiveness
0.024
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.006
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.009
CY2020 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
-0.005
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
257000 USD
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
235000 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
47579000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43241000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1899000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
1837000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
395000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
380000 USD
CY2021Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
377000 USD
CY2020Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
401000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2763000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2547000 USD
CY2021Q4 ekso Deferred Tax Assets Operating Lease Right Of Use Asset
DeferredTaxAssetsOperatingLeaseRightOfUseAsset
30000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
37000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
20000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
27000 USD
CY2021Q4 ekso Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
28000 USD
CY2020Q4 ekso Deferred Tax Liabilities Operating Lease Liability
DeferredTaxLiabilitiesOperatingLeaseLiability
88000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
32000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
53260000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
48673000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
4587000 USD
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
3192000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
645000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
637000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
1000 USD
CY2021Q4 us-gaap Purchase Obligation
PurchaseObligation
1446000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
22000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
7000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
668000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
645000 USD
CY2021Q4 ekso Number Of License Agreements
NumberOfLicenseAgreements
2 license_agreement
CY2021Q4 us-gaap Contractual Obligation
ContractualObligation
2406000 USD
CY2021Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
323000 USD
CY2021Q4 us-gaap Contractual Obligation Due In Third Year
ContractualObligationDueInThirdYear
2083000 USD
CY2021Q4 us-gaap Contractual Obligation Due In Fifth Year
ContractualObligationDueInFifthYear
0 USD
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2021 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11246000 USD
CY2021 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4497000 USD
CY2021 us-gaap Gross Profit
GrossProfit
6749000 USD
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD
CY2020 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
3812000 USD
CY2020 us-gaap Gross Profit
GrossProfit
5070000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11246000 USD
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8882000 USD

Files In Submission

Name View Source Status
0001549084-22-000006-index-headers.html Edgar Link pending
0001549084-22-000006-index.html Edgar Link pending
0001549084-22-000006.txt Edgar Link pending
0001549084-22-000006-xbrl.zip Edgar Link pending
ekso-20211231.htm Edgar Link pending
ekso-20211231.xsd Edgar Link pending
ekso-20211231_cal.xml Edgar Link unprocessable
ekso-20211231_def.xml Edgar Link unprocessable
ekso-20211231_htm.xml Edgar Link completed
ekso-20211231_lab.xml Edgar Link unprocessable
ekso-20211231_pre.xml Edgar Link unprocessable
exhibit21112312021.htm Edgar Link pending
exhibit23112312021.htm Edgar Link pending
exhibit23212312021.htm Edgar Link pending
exhibit31112312021.htm Edgar Link pending
exhibit31212312021.htm Edgar Link pending
exhibit32112312021.htm Edgar Link pending
exhibit32212312021.htm Edgar Link pending
exhibit41012312021.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending